CompletedPHASE1, PHASE2NCT02363322

Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Studying Ebola hemorrhagic fever

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Richard T Davey, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Intervention: B/Current Standard of Care Plus ZMapp(drug)
Enrollment: 72 enrolled
Eligibility: All sexes
Timeline: 2015 – 2017

Study locations (11)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
CTE Forecariah, Forécariah, Guinea
Monrovia Medical Unit, Monrovia, Liberia
ELWA III Hospital, Paynesville, Liberia
Police Training School 1 (PTS1), Western Rural District, Freetown, Sierra Leone
Emergency Ebola Treatment Unit, Goderich, Sierra Leone
Police Training School 2, Hastings, Sierra Leone
Chinese Friendship Hospital, Jui, Sierra Leone
International Medical Corps (IMC) Kambia, Kambia, Sierra Leone
International Medical Corps (IMC) Lunsar, Port Loko, Sierra Leone
Adventist Development and Relief Ebola Treatment Unit, Waterloo, Sierra Leone

Collaborators

The Ministry of Health and Social Welfare, Liberia · Ministry of Health and Sanitation, Sierra Leone · Institut National de la Santé Et de la Recherche Médicale, France · The Ministry of Health and Public Hygiene, Guinea

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02363322 on ClinicalTrials.gov

Other trials for Ebola hemorrhagic fever

Additional recruiting or active studies for the same condition.

See all trials for Ebola hemorrhagic fever →

← Back to all trials